Surface Oncology Announces Initiation Of Phase 2 Studies Evaluating SRF388 In Patients With Hepatocellular Carcinoma And Non-Small-Cell Lung Cancer
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche
Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients
Surface Oncology Highlights New SRF388 Data At AACR Meeting
Surface Oncology Inc (NASDAQ: SURF) announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Surface Oncology Achieves $30M Milestone With First Patient Dosed In GlaxoSmithKline Phase 1 Study
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.